Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 12/20 | 0.44 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.41 |
| ▸ | BTK | Q06187 | 2/20 | 0.40 |
| ▸ | JAK3 | P52333 | 1/20 | 0.40 |
| ▸ | AURKA | O14965 | 3/20 | 0.38 |
| ▸ | PDPK1 | O15530 | 3/20 | 0.38 |
| ▸ | AURKB | Q96GD4 | 3/20 | 0.38 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5437005 | 0.93 | DPP4 (0.45) | DPP4MAP4K4BTKJAK3AURKA | |
| SCHEMBL5444485 | 0.84 | ALDH1A1 (0.47) | DPP4MAP4K4BTKJAK3 | |
| SCHEMBL556855 | 0.84 | DPP4 (0.45) | DPP4MAP4K4BTKJAK3AURKA | |
| SCHEMBL5431270 | 0.82 | DPP4 (0.52) | DPP4MAP4K4BTKJAK3 | |
| SCHEMBL554976 | 0.82 | MAPK1 (0.54) | DPP4 | |
| SCHEMBL637617 | 0.82 | MAPK1 (0.54) | DPP4 | |
| SCHEMBL555316 | 0.82 | MAPK1 (0.54) | DPP4 | |
| SCHEMBL556010 | 0.81 | DPP4 (0.44) | DPP4 | |
| SCHEMBL762961 | 0.79 | MAP4K4 (0.51) | DPP4MAP4K4BTKJAK3AURKA | |
| SCHEMBL555427 | 0.79 | DPP4 (0.48) | DPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070105890-A1 | Novel condensed imidazole derivative | DAINIPPON SUMITOMO PHARMA CO., LTD | 2007-05-10 | — | — | US | disclosed |
| US-20070105890-A1 | Novel condensed imidazole derivative | DAINIPPON SUMITOMO PHARMA CO., LTD | 2007-05-10 | — | — | US | disclosed |
| EP-1690863-A1 | NOVEL CONDENSED IMIDAZOLE DERIVATIVE | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2006-08-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070105890-A1 | Novel condensed imidazole derivative | DPP4, DPP7, DPP3 | DPP4 1/4885MAP4K4 708/4885BTK 3206/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.